NCT01728792View on ClinicalTrials.gov

Impact of SC vs IM Administration of DENVax (TDV) on Safety and Immunogenicity

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 22, 2013

Primary Completion Date

November 1, 2013

Study Completion Date

November 21, 2013

Conditions
Dengue Fever
Interventions
BIOLOGICAL

TDV

TDV IM or SC injection

Trial Locations (1)

13210

SUNY Upstate Medical University, Syracuse

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
collaborator

Walter Reed Army Institute of Research (WRAIR)

FED

lead

Takeda

INDUSTRY